MNT speaks with three obesity medicine experts to find out more about the FDA-aproved Wegovy pill and how it's different from ...
Please provide your email address to receive an email when new articles are posted on . The decision is supported by positive visual acuity gains found in the phase 3 QUASAR trial. This is the fourth ...
On Wednesday, the U.S. Food and Drug Administration (FDA) approved Regeneron Pharmaceuticals Inc.’s (NASDAQ: REGN) Eylea HD (aflibercept) Injection 8 mg for patients with macular edema following ...
The approvals come as a pleasant surprise for Regeneron, analysts say, helping bolster the overall product profile of high-dose Eylea despite outstanding manufacturing concerns. Regeneron’s high-dose ...
Results showed both aflibercept 8mg dosing arms were noninferior and clinically equivalent to Eylea based on the change in BCVA score at week 36. The Food and Drug Administration (FDA) has approved ...
TARRYTOWN, N.Y., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA HD ® (aflibercept) ...
The agency approved a monthly dosing option for select patients acorss all approved indications, including wAMD, DME, DR, and RVO. FDA approved aflibercept (Eylea HD) 8 mg for macular edema following ...
Eylea is a brand-name biologic prescription medication containing the active ingredient aflibercept. Generic versions of biologic drugs are called biosimilars. Due to the complex manufacturing process ...
TARRYTOWN, N.Y., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has extended the target action dates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback